# Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Source: https://onco.cc/trials/nct05862337/  
OnCo record `nct05862337` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Anlotinib, Penpulimab in hepatocellular carcinoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.

## Summary

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. is a phase 3 interventional study registered as NCT05862337 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 480 participants planned, started 2023-05-10 and due to reach its primary completion in 2024-08. Interventions recorded: Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05862337
- Phase: 3
- Setting: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study of Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection in Patients With High Risk of Relapse After Radical Surgery or Ablation of Hepatocellular Carcinoma (HCC).
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrolled: 480

## Sources

- ClinicalTrials.gov NCT05862337: https://clinicaltrials.gov/study/NCT05862337

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Penpulimab](https://onco.cc/drugs/penpulimab/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct05862337.json